Table 1 Baseline characteristics of SFTS patients according to AKI stage.
From: Acute kidney injury as a prognostic marker in severe fever with thrombocytopenia syndrome
Total (n = 53) | Non-AKI (n = 26) | AKI stage 1 (n = 17) | AKI stage 2 + 3 (n = 10) | P-value | |
|---|---|---|---|---|---|
Sex, male (%) | 29(54.7%) | 15(57.7%) | 7(41.2%) | 7(70.0%) | 0.318 |
Age, years | 66.5 ± 15.5 | 61.4 ± 17.4 | 69.5 ± 13.5 | 74.7 ± 7.7 | 0.041 |
Current smoking (%) | 41(77.4%) | 17(65.4%) | 15(88.2%) | 9(90.0%) | 0.123 |
Comorbidity | |||||
Hypertension | 24(45.3%) | 9(34.6%) | 9(52.9%) | 6(60.0%) | 0.291 |
Diabetes mellitus | 11(20.8%) | 2(7.7%) | 4(23.5%) | 5(50.0%) | 0.019 |
Chronic liver disease | 5(9.4%) | 2(7.7%) | 2(11.8%) | 1(10.0%) | 0.903 |
Cerebrovascular disease | 2(3.8%) | 1(3.8%) | 1(5.9%) | 0(0.0%) | 0.741 |
Heart disease | 3(5.7%) | 0(0.0%) | 3(17.6%) | 0(0.0%) | 0.034 |
Solid tumor | 4(7.5%) | 2(7.7%) | 2(11.8%) | 0(0.0%) | 0.535 |
Physical findings | |||||
Conjunctival injection | 3(5.7%) | 1(3.8%) | 2(11.8%) | 0(0.0%) | 0.378 |
Lymphadenopathy | 6(11.3%) | 4(15.4%) | 2(11.8%) | 0(0.0%) | 0.426 |
Tick-bite lesions | 26(49.1%) | 13(50.0%) | 10(58.8%) | 3(30.0%) | 0.348 |
Systemic signs and symptoms | |||||
Fever | 48(90.6%) | 24(92.3%) | 16(94.1%) | 8(80.0%) | 0.438 |
Myalgia | 30(56.6%) | 17(65.4%) | 8(47.1%) | 5(50.0%) | 0.444 |
Back pain | 2(3.8%) | 1(3.8%) | 1(5.9%) | 0(0.0%) | 0.741 |
Sore throat | 5(9.4%) | 3(11.5%) | 0(0.0%) | 2(20.0%) | 0.201 |
General weakness | 26(49.1%) | 9(34.6%) | 9(52.9%) | 8(80.0%) | 0.047 |
Skin rash | 7(13.2%) | 4(15.4%) | 3(17.6%) | 0(0.0%) | 0.383 |
Respiratory and cardiovascular signs and symptoms | |||||
Cough | 4(7.5%) | 1(3.8%) | 1(5.9%) | 2(20.0%) | 0.247 |
Sputum | 6(11.3%) | 3(11.5%) | 2(11.8%) | 1(10.0%) | 0.989 |
Dyspnea | 2(3.8%) | 0(0.0%) | 2(11.8%) | 0(0.0%) | 0.111 |
Chest pain | 1(1.9%) | 1(3.8%) | 0(0.0%) | 0(0.0%) | 0.589 |
Gastrointestinal signs and symptoms | |||||
Anorexia | 24(45.3%) | 14(53.8%) | 7(41.2%) | 3(30.0%) | 0.401 |
Nausea | 16(30.2%) | 7(26.9%) | 7(41.2%) | 2(20.0%) | 0.450 |
Vomiting | 9(17.0%) | 4(15.4%) | 3(17.6%) | 2(20.0%) | 0.943 |
Diarrhea | 27(50.9%) | 13(50.0%) | 9(52.9%) | 5(50.0%) | 0.980 |
Abdominal pain | 15(28.3%) | 6(23.1%) | 6(35.3%) | 3(30.0%) | 0.679 |
Hemorrhagic signs and symptoms | |||||
Oral bleeding | 2(3.8%) | 1(3.8%) | 1(5.9%) | 0(0.0%) | 0.741 |
Gastrointestinal bleeding | 1(1.9%) | 0(0.0%) | 0(0.0%) | 1(10.0%) | 0.112 |
Petechiae | 2(3.8%) | 0(0.0%) | 1(5.9%) | 1(10.0%) | 0.317 |
Neurologic signs and symptoms | |||||
Headache | 13(24.5%) | 8(30.8%) | 3(17.6%) | 2(20.0%) | 0.579 |
Dizziness | 12(22.6%) | 6(23.1%) | 4(23.5%) | 2(20.0%) | 0.975 |
Altered mentality | 20(37.7%) | 5(19.2%) | 8(47.1%) | 7(70.0%) | 0.012 |
